By a News Reporter-Staff News Editor at Pharma Business Week -- Investigators publish new report on Skin Diseases and Conditions - Atopic Dermatitis. According to news reporting from Tokyo, Japan, by NewsRx journalists, research stated, "Little attention has been given to the burden of chronic urticaria (CU) in Japan compared with other skin diseases, such as atopic dermatitis (AD) and psoriasis. The primary objective of the RELEASE study was to evaluate the real-life quality-of-life impairment in CU patients in Japan."
Financial support for this research came from Novartis Pharma K.K., Tokyo, Japan (see also Skin Diseases and Conditions - Atopic Dermatitis).
The news correspondents obtained a quote from the research from Novartis, "Data were collected from 1443 urticaria, 1668 AD and 435 psoriatic patients; 552 urticaria patients who presented urticaria symptoms for over 6 weeks were defined as CU. The mean Dermatology Life Quality Index (DLQI) total score was 4.8, 6.1 and 4.8 in CU, AD and psoriatic patients, respectively. Disease control of urticaria evaluated by the Urticaria Control Test (UCT) and DLQI exhibited a strong correlation with a Spearman's rank correlation coefficient of -0.7158. CU and AD patients had relatively higher scores in all Work Productivity and Activity Impairment -General Health subscales except for absenteeism. At the time of the survey, approximately 64% of CU patients reported UCT scores of <12 and demonstrated higher work productivity loss and activity impairment versus patients with UCT scores of greater than or equal to12. Patients with lower UCT scores also displayed a higher percentage of dissatisfaction with their health state and the treatment they received. Approximately 85% of patients with CU had visited dermatology clinics, and less than 20% had visited hospital, indicating existence of a highly burdened population outside specialized centers."
According to the news reporters, the research concluded: "These results highlight the unmet medical needs of CU patients, suggesting the need to increase awareness of CU burden among both physicians and patients and to pursue improved real-life patient care."
For more information on this research see: Impact of chronic urticaria on quality of life and work in Japan: Results of a real-world study. The Journal of Dermatology, 2018;():. The Journal of Dermatology can be contacted at: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.
Our news journalists report that additional information may be obtained by contacting A. Itakura, Novartis Pharma K.K., Tokyo, Japan. Additional authors for this research include Y. Tani, N. Kaneko and M. Hide.
Publisher contact information for the The Journal of Dermatology is: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.
Keywords for this news article include: Pharmaceutical Companies, Tokyo, Business, Urticaria, Dermatology, Quality of Life, Atopic Dermatitis, Health and Medicine, Immediate Hypersensitivity, Vascular Skin Diseases and Conditions.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC